Irish life sciences VC firm Seroba closes out €123m fund

Fund IV to target 12 investments with Irish companies Perfuze and Deciphex among those that have already received backing

Since its launch, Seroba has invested in 32 life sciences companies, bringing to market 20 new medical devices and eight new therapeutics to date. Picture Bloomberg

Seroba, the Irish life sciences venture capital firm, has announced the final close of its latest fund at €123 million.

The fund is to be used to target companies that are developing novel treatments addressing major unmet medical needs. Up to 12 investments are expected to be made under Fund IV.

Seroba said the fund will focus on life sciences firms in Western Europe, and selectively in North America. Five companies have already received investment ...